DRUGS药物
DRUGS(英文缩写 DRUGS),ISSN 0012-6667,eISSN 1179-1950,中文译名:药物 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 11.431 | Q1 |
| 2022 | 11.500 | Q1 |
| 2023 | 13.000 | Q1 |
| 2024 | 14.400 | Q1 |
| 2025 | 14.700 | Q1 |
DRUGS 最新收录文献
-
1. Infections and the Opioid Epidemic: Changing Epidemiology and Treatment Options.
1. 感染和阿片类药物流行：不断变化的流行病学和治疗选择PMID:日期:2026-10-04The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating mortality, with over 80,000 opioid-involved overdose deaths in the USA in 2022. Despite the proven effectiveness of opioid agonist therapy, specifically methadone and buprenorphine, treatment coverage remains inadequate, with profound gaps in opioid use disorder (OUD) continuum of care. Injection-related infections, particularly skin and soft tissue infections, bacteremia, osteomyelitis, and infective endocarditis, have increased substantially since the early 2000s and carry a high risk of morbidity and mortality. Risk is further compounded by criminalization, stigma, incarceration, and comorbid psychiatric conditions. Emerging concerns such as xylazine-associated necrotic wounds illustrate the dynamic intersection of substance use and infectious disease. While direct-acting antivirals have made hepatitis C curable, barriers to treatment persist, and uptake of HIV prevention strategies, including pre-exposure prophylaxis, remains low among people who inject drugs. Integration of addiction treatment into infectious disease and hospital care improves outcomes, yet systemic and policy barriers limit access. Innovative models such as syringe service programs, mobile units, and inpatient addiction consult services demonstrate the feasibility of integrated, patient-centered care. Evidence gaps remain regarding optimal antibiotic strategies for serious infections in people with OUD, and research and policy must address exclusionary practices, stigma, and fragmented systems of care. A synergistic approach integrating OUD treatment, infectious disease management, risk reduction, and trauma-informed care is essential to reduce preventable deaths and improve long-term health outcomes.
-
2. Personalized Treatment of Hemophilia: Matching Therapies to Patient Needs in a Rapidly Evolving Landscape.
2. 血友病的个性化治疗：在快速发展的格局中将治疗与患者需求相匹配PMID:日期:2026-09-25The therapeutic landscape of hemophilia, a rare inherited bleeding disorder, has rapidly evolved, introducing several novel modalities: extended half-life (EHL) coagulation factor concentrates, non-factor therapies, hemostasis-rebalancing agents, and gene therapy. These advances have improved clinical outcomes by reducing bleeding and treatment burden. However, individualizing treatment in routine practice has become more complex. This narrative review aims to provide a practical summary of available treatment options for pharmacologists, policymakers, and other readers who are not hemophilia specialists. A practical decision framework integrates available data with the clinical indication (regular prophylaxis, management of breakthrough bleeding, and perioperative care), patient-specific modifiers (age, lifestyle, inhibitor status, venous access, joint phenotype, comorbidities, and thrombosis risk). Drug therapies are discussed according to clinical evidence, including pivotal phase 3 trials, long-term extension studies, real-world data, and late-stage development programs. Factor replacement remains critical for hemostatic control during acute bleeding, surgery, and other interventions where predictable and measurable exposure is needed, whereas non-factor and rebalancing therapies provide low-burden prophylactic alternatives with distinct safety profiles and monitoring challenges. Direct comparisons between treatment classes are limited, making treatment individualization essential. Gene therapy has demonstrated more durable outcomes in hemophilia B than in hemophilia A. This review supports shared decision-making and individualized treatment selection in modern hemophilia care. While clinical trial evidence is limited by the scarcity of head-to-head comparisons and incomplete integration of real-world determinants, registry data collection will be essential.
-
3. Camizestrant: First Approval.
3. 移民：首次批准PMID:日期:2026-09-25Camizestrant (Etcamah) is an orally available, potent selective estrogen receptor degrader (SERD) and complete estrogen receptor (ER) α antagonist being developed by AstraZeneca for the treatment of breast cancer. It received its first approval in the United Arab Emirates (UAE) in May 2025. At the time of writing, the drug had been subsequently approved in Saudi Arabia, Japan, the EU, Canada, the UK and the USA. In patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a detectable ESR1 mutation, switching to camizestrant while continuing the same CDK4/6 inhibitor significantly prolonged progression-free survival in comparison with continuing treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor. This article summarizes the milestones in the development of camizestrant leading to this first approval for the treatment of adults with locally advanced or metastatic hormone receptor positive (HR+), HER2-negative breast cancer with an ESR1 gene mutation that emerges during first-line hormonal therapy, in combination with CDK4/6 inhibitors.
-
4. Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.
4. IGF-1受体抑制剂治疗甲状腺眼病的疗效与安全性：随机对照试验的系统评价与Meta分析PMID:日期:2026-09-24Insulin-like growth factor-1 receptor (IGF-1R) inhibitors represent the first and currently only US Food and Drug Administration (FDA)-approved disease-modifying therapy for thyroid eye disease (TED). Understanding their efficacy and safety is essential for treatment decision-making. A comprehensive analysis of randomized controlled trial (RCT) data of these drugs is necessary for defining reliably improved outcomes and commonly observed treatment-related adverse events. In this study, we aimed to evaluate the efficacy and safety profiles of IGF-1R inhibitors for treatment of TED as evidenced by RCTs. This systematic review and meta-analysis was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251141789) and conducted according to Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidelines. PubMed, Embase, Web of Science, Cochrane Library, and EBSCO were searched through 10 December 2025. Eligible studies were RCTs comparing IGF-1R inhibitors with placebo in TED. Two reviewers independently performed study selection, data extraction, and quality assessment using the Cochrane risk of bias tool. Fixed- or random-effects models, selected according to the degree of statistical heterogeneity, were used to estimate pooled risk ratios (RRs) and mean differences (MDs), with subgroup, meta-regression, and sensitivity analyses exploring heterogeneity. A total of 669 patients participating in 7 RCTs were included from 957 articles screened. These include studies evaluating teprotumumab, IBI311, and veligrotug. Regarding primary outcomes, IGF-1R inhibitors improved proptosis significantly (RR = 7.71, 95% CI 5.04-11.79, P < 0.001) and increased overall response (RR = 8.74, 95% CI 5.61-13.62, P < 0.001). Secondary outcome analysis revealed a significant improvement with IGF-1R inhibitors versus placebo, including achieving clinical activity score (CAS) of 0 or 1 (RR = 3.19, 95% CI 2.40-4.24, P < 0.001), diplopia (RR = 1.95, 95% CI 1.52-2.50, P < 0.001), least squares mean (LSMean) change in proptosis (MD = - 2.22 mm, 95% CI - 2.45 to - 1.99 mm, P < 0.001) and LSMean change in quality of life (MD = 10.48, 95% CI 6.95-14.00, P < 0.001). Pooled adverse-event rate was higher in the active treatment group (RR = 1.15, 95% CI 1.06-1.24, P < 0.001). Subgroup analysis and meta-regression identified disease activity as a significant predictor of proptosis reduction, with greater efficacy in acute active TED, while an exploratory subgroup difference in diplopia response was observed between trials conducted in predominantly white and predominantly East Asian populations (P(Qint) = 0.027). IGF-1R inhibitors outperformed placebo across multiple efficacy outcomes. These findings confirm their robust efficacy in TED, particularly in active disease. Given the increased adverse event risk, IGF-1R inhibitors warrant vigilant monitoring, including baseline and on-treatment glycemic and audiometric assessments, to ensure optimal safety.
-
5. Pharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Progress and Successes.
PMID:日期:2026-09-23Irritable bowel syndrome with constipation is a prevalent disorder of gut-brain interaction in children and adolescents, associated with chronic abdominal pain, altered bowel habits, reduced quality of life, and a significant healthcare burden. Despite a wide range of therapeutic approaches, treatment responses remain suboptimal, highlighting the need for effective, evidence-based pharmacological options. This review summarizes current and emerging pharmacological therapies for pediatric irritable bowel syndrome with constipation, with a focus on their mechanisms of action, efficacy, and safety. Traditional treatments such as dietary fiber, probiotics, antispasmodics, laxatives, prokinetics, antidepressants, antibiotics, and antihistamines are reviewed, emphasizing the limited and often inconsistent evidence supporting their use for pain relief and overall symptom improvement. Particular attention is given to newer agents approved for adults with irritable bowel syndrome with constipation, including secretagogues (linaclotide, plecanatide, and lubiprostone) and the retainagogue tenapanor, with a detailed discussion of their pharmacological properties and clinical trial data. Linaclotide is currently the only medication approved by the U.S. Food and Drug Administration for the treatment of irritable bowel syndrome with constipation in children aged 7 years or older. While other novel agents have shown promise in adults, pediatric data remain limited or unavailable. Overall, although pharmacological treatment options for pediatric irritable bowel syndrome with constipation are expanding, high-quality, pediatric specific clinical trials are still needed to guide safe and effective management.
-
6. Vaccination for Gonorrhoea: Where Are We Now, and What Comes Next?
PMID:日期:2026-09-22Gonorrhoea, caused by Neisseria gonorrhoeae, is a common bacterial sexually transmitted infection and a major global health burden, with more than 80 million new cases estimated annually. There is currently no licensed vaccine, and increasing antimicrobial resistance has renewed the urgency of vaccine development. However, vaccines licensed to prevent invasive meningococcal disease, caused by the closely related bacterium Neisseria meningitidis, may provide cross-protection against N. gonorrhoeae. Observational studies have associated outer membrane vesicle-containing serogroup B meningococcal vaccines with reduced gonorrhoea rates, with estimated effectiveness of approximately 30%. The four-component meningococcal group B vaccine (4CMenB) contains antigens with gonococcal homologues and induces cross-reactive immune responses in both humans and animal models. These findings have supported the implementation of targeted 4CMenB immunisation programmes for people at high risk of gonorrhoea in the UK and Galicia, Spain. However, the recently reported GoGoVax trial and other randomised controlled trials in men who have sex with men (MSM) at high risk of infection have not demonstrated protection against gonorrhoea. Differences in study design, populations, exposure intensity, endpoints and residual confounding may explain the divergence between observational and randomised findings. Ongoing trials in other populations, together with post-implementation surveillance in the UK, will provide important evidence regarding the effectiveness of 4CMenB in different settings. Several gonococcus-specific vaccine candidates are also advancing through preclinical and clinical development. Future progress will benefit from validated correlates of protection, improved understanding of protective mucosal immunity across different anatomical sites and evaluation of vaccine efficacy across diverse populations and exposure settings.
-
7. Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.
7. 回肠储袋肛管吻合术后抗生素难治性慢性储袋炎：当前及新兴的治疗策略PMID:日期:2026-09-16Chronic inflammatory pouch disorders may affect up to 20% of patients within 5 years after ileal pouch-anal anastomosis and remains a major therapeutic challenge. Within this spectrum, chronic antibiotic-refractory pouchitis is associated with impaired quality of life, long-term pouch-related complications, and potential risk for pouch failure and excision. Current recommendations support the use of probiotics for primary and secondary prevention in selected patients. Increasingly, targeted advanced therapies, including biologics and small molecules approved for the treatment of ulcerative colitis and Crohn's disease, are being used to reduce antibiotic dependence and maintain disease control in patients with pouch inflammation. Vedolizumab is the only advanced therapy approved in Europe for chronic pouchitis, whereas evidence for tumor necrosis factor (TNF) antagonists, ustekinumab, and newer agents, such as interleukin (IL)-23p19 antagonists and Janus kinase (JAK) inhibitors is largely based on observational data from clinical practice and real-world experience. Fecal microbiota transplantation is biologically attractive but remains investigational, with early studies showing inconsistent efficacy. Dietary patterns may modify pouch inflammation; however, most evidence is observational. Overall, current management strategies for chronic pouchitis are limited by incomplete understanding of disease pathogenesis, and by persistent methodological gaps, including poorly standardized treatment outcomes and the lack of validated treat-to-target strategies for this population. Well designed prospective and controlled studies are needed to define appropriate antibiotic-sparing strategies, optimal treatment positioning, and long-term durability of response.
-
8. Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
8. 代谢功能障碍相关脂肪性肝病（MASLD）的当前及新兴生物标志物与替代终点PMID:日期:2026-09-12Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a prevalent condition affecting 25-30% of the global population and is closely linked to obesity, type 2 diabetes, and other cardiometabolic risk factors. Although liver biopsy remains the gold standard for diagnosis, its invasive nature has prompted a shift toward non-invasive biomarkers for disease assessment, staging, and monitoring. Multiple non-invasive biomarkers have been studied or are currently under investigation to assess both fibrosis and steatosis among patients with MASLD. This review aims to summarize the current literature on emerging and established biomarkers for MASLD, focusing on their roles in detecting inflammation, fibrosis, metabolic dysfunction, and steatosis, including imaging-based surrogate endpoints and composite biomarker panels.
-
9. Doravirine/Islatravir: First Approval.
PMID:日期:2026-09-12Doravirine/islatravir is an oral two-drug fixed-dose combination of doravirine [a non-nucleoside reverse transcriptase inhibitor (NNRTI)] and islatravir [a nucleoside reverse transcriptase translocation inhibitor (NRTTI)]. Developed by Merck & Co., Inc., Rahway, NJ, USA, doravirine/islatravir [IDVYNSO イドビンソ (Japan); IDVYNSO™ (USA); IDVYNSO (Canada)] was first approved on 6 March 2026 in Japan and subsequently approved on 21 April 2026 in the USA and 3 June 2026 in Canada for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL). Clinical development is underway in several other countries worldwide. This article summarizes the milestones in the development of doravirine/islatravir leading to these first approvals.
-
10. Anbenitamab: First Approval.
PMID:日期:2026-09-12Anbenitamab (Ennituo), a bispecific IgG monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), is being developed by Alphamab Oncology for the treatment of various solid tumours (including gastric cancer and breast cancer). Anbenitamab received its first approval in China on 27 May 2026. Anbenitamab, in combination with chemotherapy, is approved for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received at least one trastuzumab-containing therapy. This article summarizes the milestones in the development of anbenitamab leading to this first approval for gastric or GEJ cancer.